Elevated levels of IL-6 in IgA nephropathy patients are induced by an epigenetically-driven mechanism triggered by viral and bacterial RNA

Sallustio Fabio[1], Claudia Curci[2], Maria Teresa Cimmarusti[2], Angela Picerno[1], Giuseppe De Palma[3], Carmen Sivo[2], Francesca Annese[2], Giulia Fontò[2], Alessandra Stasi[2], Francesco Pesce[2], Vincenzo Di Leo[2], Loreto Gesualdo[2].

1) Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy

2) Nephrology, Dialysis and Transplantation Unit, DETO, University "Aldo Moro" Bari, Italy

3) Institutional Biobank, Experimental Oncology and Biobank Management Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori Bari Giovanni Paolo II, Bari, Italy.

Corresponding author:

Fabio Sallustio, PhD; Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Piazza G. Cesare,11 70124 Bari, Italy; Tel./ Fax: 0039 080 5478878; Email: fabio.sallustio@uniba.it

ABSTRACT

Recently, a several models has been proposed to describe the pathogenesis of Immunoglobulin A nephropathy (IgAN), and among them the multihit and the gut-microbiota. These models explain the pathogenesis of IgAN caused by the production of aberrant IgA, but it is believed further predisposing factors are present, including immunological, genetic, environmental, or nutritional factors that can influence the pathogenesis and that could be useful for development of precision nephrology and personalized therapy.

Newly, the role of IL-6 in pathogenesis is becoming increasingly important. It is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice, even if the reason why levels of IL-6 are elevated in IgAN patients is not well understood. One attainable hypothesis on high levels of IL-6 in IgAN comes out from our recent whole genome DNA methylation screening in IgAN patients, that identified, among others, a hypermethylated region comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA also known as precursor of miR-886 (pre-mi-RNA). Consistently, the VTRNA2-1 expression was found down-regulated in IgAN patients.

Here we confirm that VTRNA2-1 is low expressed in IgAN subjects compared to HS and we found that also in transplanted IgAN patients (TP-IgAN), compared to non IgAN transplanted patients (TP), the VTRNA2-1 transcript was expressed at level very low. We found that in IgAN patients with downregulated VTRNA2-1, PKR is overactivated, coherently with the role of the VTRNA2-1 that binds to PKR and inhibits its phosphorylation. The loss of the VTRNA2-1 natural restrain causes, in turn, the activation of CREB by PKR. We found CREB, a classical cAMP-inducible CRE-binding factor interacting with a region of the IL-6 promoter and leading to IL-6 production, overactivated both in IgAN and in TP-IgAN patients. Effectively, in the same patients, we found elevated levels of IL-6 correlating with CREB and PKR phosphorylation.

Since PKR is normally activated by bacterial and viral RNA we hypothesized that these microrganisms can further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 production, explaining both the high levels of IL-6, both infection involvement in the disease, both cases of IgAN associated with COVID-19 infection and with COVID-19 RNA-vaccination, and recent data showing microbiota involvment in IgAN.

Effectively, we found that Effectively, we sfound that both the RNA poly(I:C) and the COVID-19 RNA-vaccine stimulation significantly increase the IL-6 levels in IgAN patient PBMCs.

The PKR/CREB/IL-6 pathway may be very important also in the setting of renal transplantation. We found that this pathway is upregulated also in IgAN transplanted patients. Recent studies showed that the cumulative risk of IgA nephropathy recurrence increases after transplant and is associated with a 3.7-fold greater risk of graft loss. Finally, we showed that the IL-6 secretion can be reduced by the PKR inhibitor imoxin.

In conclusion, the discovery of the upregulated VTRNA2-1/PKR/CREB/IL-6 pathway in IgAN patients may provide novel approach to treat the disease and may be useful for development of precision nephrology and personalized therapy, possibly by checking the VTRNA2-1 methylation level in IgAN patients.

65 **INTRODUCTION**

66 Immunoglobulin A nephropathy (IgAN), also known as Berger's disease, is the most frequent primary
67 glomerulonephritis characterized by the presence of IgA immune complexes in the glomeruli (1). It
68 generally appears in the second and third decade of life, has a higher incidence in males and it is more
69 common in whites than in blacks with a higher prevalence in Asians than Caucasians(1).

70 Recently, a multihit model has been proposed to describe the pathogenesis of IgAN. In this model,
71 the first hit is given by the hypersecretion of deglycosylated IgA (Gd-IgA1)(2). In circulation, these
72 Gd-IgA1 are recognized and attacked by autoantibodies (second hit) and this process leads to the
73 formation of circulating immune complexes (third hit), some of which are deposited at the mesangial
74 level in the glomeruli(2). Kidney damage resulting from the deposition of the cells is characterized
75 by local inflammation, complement activation, cell proliferation, and finally fibrosis(3).

76 Moreover, in humans, the gut-associated lymphoid tissue (GALT) is the primary source of IgA, so
77 the pathogenesis of IgAN is related to gut homeostasis. Indeed, the intestinal–renal axis is important
78 in Berger's glomerulonephritis, where several factors (e.g. genetics(4,5), infections(6,7), and food
79 antigens (8) may play a role in the disease complex pathogenesis and provide novel therapeutic targets
80 to modify disease evolution.

81

82 These models explain the pathogenesis of IgAN caused by the production of aberrant IgA, but it is
83 believed further predisposing factors are present, including immunological, genetic, environmental,
84 or nutritional factors that can influence the pathogenesis and that could be useful for development of
85 precision nephrology and personalized therapy.

86 We have recently showed that IgAN patients have a higher frequency of intestinal-activated B cells
87 than healthy subjects (HS). IgAN patients had greater BAFF cytokine blood levels, which were linked
88 to higher levels of five microbiota metabolites, and high APRIL cytokine serum levels. In comparison
89 to HS, IgAN individuals had a larger number of circulating gut-homing (CCR9 β7 integrin) regulatory
90 B cells, memory B cells, and IgA memory B cells(9).

91 Moreover, several studies have shown the involvement of the IL-6 pathway in IgAN. Interleukin-6 is
92 essential for glomerular immunoglobulin A deposition and the development of renal pathology in
93 Cd37-deficient mice (10), Moreover, the proliferation-inducing ligand (APRIL) and IL-6 are
94 involved in the overproduction of aberrantly glycosylated IgA. In mice, the APRIL silencing blocked
95 the overproduction of Gd-IgA1 induced by IL-6 and, conversely, neutralizing IL-6, the production of
96 Gd-IgA1 was reduced(11). Interestingly, the mycotoxins deoxynivalenol (DON) prolonged exposure
97 cause the expansion of IgA secreting B cells by activating macrophages and T cells. In mice it results
98 in the early stages of human IgA nephropathy(12,13) and the overproduction of inflammatory
99 interleukins such as IL-6(14), which in turn induces upregulation of IgA.
100
101 However, to date, the biological mechanisms leading to the elevate IL6 levels in IgAN patients are
102 not clear. In a recent study, a whole-genome screening was performed for DNA methylation in $CD4^+$
103 T cells from IgAN patients, identifying three regions with altered methylation capable of influencing
104 the gene expression of genes involved in cell response and proliferation T $CD4^+$(15). In particular, a
105 hypermethylated region was identified comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA
106 also known as the precursor of miR-886 (Pre-mi-RNA).
107
108 Here we studied the VTRNA2-1/PKR/CREB/IL-6 pathway showing that it is upregulated in IgAN
109 patients and that it is responsible for the elevated IL-6 levels characterizing the disease, thus providing
110 for the first time an explanation on the abnormal levels of this cytokine. We found that this pathway
111 is epigenetically controlled by VTRNA2-1 and triggered by bacterial and viral infections. It can
112 explain both the high levels of IL-6 both the correlation to mucosal infections of the disease. Finally,
113 we showed how the imoxin inhibitor, targeting this pathway, can reduce IL-6 secretion by PBMCs of
114 IgAN patients providing a new possible approach to treat the disease.
115
116

117 **RESULTS**

118

119 **VTRNA2-1 is downregulated in IgAN patients**

120 Recently, we showed that the non-coding RNA VTRNA2-1 was epigenetically downregulated in
121 IgAN patients(15). Since we hypothesize that it may be implicated in the pathway for the secretion
122 of IL-6, we further confirm the involvement of VTRNA2-1 in IgAN studying its expression in
123 PBMCs isolated from IgAN patients and healthy subjects.

124 VTRNA2-1 was strongly downregulated in IgAN patients compared to healthy subjects showing a
125 decrease of 30 fold ($p < 0.05$, Figure 1A). Moreover, recent clinical observations have shown that IL-
126 6 production is implicated in renal allograft rejection(16,17) and that cumulative risk of IgA
127 nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of
128 graft loss (17).

129 We therefore analysed the expression of VTRNA2-1 in PBMCs isolated from IgAN patients with
130 kidney transplant (T-IgAN) and in patients non-IgAN with kidney transplant (TP). Also in this case,
131 we found that the VTRNA2-1 was extremely downregulated in transplanted IgAN patients compared
132 to their controls ($p<0.0001$, fold change=100; Figure 1B), confirming that this modulation is a
133 characteristic of IgAN disease.

134



Figure 1. VTRNA2-1 expression in real-time PCR. (A)Real-time PCR of VTRNA2-1 transcript differentially expressed in PBMCs of IgAN and HS. (B) Real-time PCR of VTRNA2-1 transcript differentially expressed in PBMCs of T-IgAN and TP. Data are expressed as mean ± SEM, (* p-value < 0.05, ****p-value <0.001).

Downregualtion of VTRNA2-1 In IgAN patients lead to the increase in phosphorilated PKR.

VTRNA2-1 can inhibit PKR, an interferon-inducible and double-stranded RNA (dsRNA) dependent kinase, by binding to this protein and preventing its auto-phosphorylation(18). Thus, we studied whether in the IgAN patients with low levels of VTRNA2-1 the correspective upregulation of the PKR signalling was present. We measured the levels of the phosphorilated (pPKR) and of the total PKR and found that in IgAN patients the level of pPKR protein normalized on the total PKR was significantly increased compared to HS (FC 2.6; $p<0.05$; Fig. 2A). At the same manner, also in T-IgAN we found the doubling of pPKR levels compared to TP (FC 2, $p<0.05$; Fig. 2B).

To confirm that the incerase in pPKR levels was due to the auto-phosphorylation induced by the lack of VTRNA2-1 and not by a different mechanism regulating the gene expression, we checked the PKR mRNA levels in IgAN patients and in HS. We found no significant differences between the two group

152 (Figure 2C). However, in T-IgAN compared to TP we found rather a decrease of the PKR transcripts
153 (Figure 2D, P<0.0001), making data of the pPKR increase even more meaningful.



154

155 **Figure 2. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated PKR**
156 (A) ELISA assay showed significantly increased level of phosphorylated PKR in IgAN patients respect to healthy
157 group (HS). (B) A strong increase in phospho-PKR levels was found in T-IgAN patients compared to TP group. (C)
158 Gene expression of PKR in IgAN patients and HS. (D) Gene expression of PKR in TP and T-IgAN patients. Data
159 are representative of 8 independent experiments (means ±SEM; * p-value < 0.05).

160

161

162 **Phosphorilation of PKR corresponds to CREB activation in IgAN patients**

163 In mice pPKR induced the Cyclic adenosine monophosphate (AMP) response element-binding
164 protein (CREB) activation by increasing its phosphorilation (12). We studied whether in IgAN
165 patients CREB phosphorilation levels were higher compared to HS. A significant 3-fold increase of
166 pCREB levels was found in IgAN patients compared to HS (p<0.01; Fig. 3 A). Also in T-IgAN
167 pCREB levels were significantly increase compared to TP, even if to less extent (1.67 fold, p<0.01;
168 Fig. 3B). However, no significant difference in CREB gene expression was present among IgAN

169 patients and HS (Figure 3C), nor in TX compared to T-IgAN (Fig. 3D), corroborating the data of
170 CREB phosphorilation in IgAN patients.



171

172 **Figure 3. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated CREB** (A) The assay
173 revealed systemic activation of CREB (phospho-Thr305-CREB) in IgAN group compared to healthy subjects (HS).
174 (B) CREB phosphorylation was also significantly increased in T-IgAN patients compared to transplanted patients
175 without IgAN disease. (C) Gene expression of CREB in IgAN patients and HS. (D) Gene expression of CREB in
176 TP and T-IgAN patients. Data are representative of 8 independent experiments (means ±SEM; * p-value < 0.05,
177 ****p-value <0.001).

178

179 **CREB activation by phosphorilation leads to IL-6 incerase in IgAN patients.**

180 Since several studies showed that CREB activation may lead to IL-6 expression(20–24), we analyzed
181 the IL-6 levels secreted by PBMCs in our IgAN patient groups. IL-6 levels showed a statistically
182 significant increase in IgAN patients compared to HS ($p<0.05$; Fig. 4A). In T-IgAN compared to TP
183 a tendence in increased levels of IL-6 was found, even if it is not significant (Fig. 4B). Both the levels
184 of pCREB and pPKR significantly correlated with IL-6 levels in IgAN patients ($r=0.97$, $p= 0.0006$

185 and r=0.89, p=0.0064, respectively), indicating that the high levels of this cytokine are due to the

186 VTRNA2-1/pPKR/pCREB signalling epigenetically regulated (Figure 4C-D).

187



188

189

190 **Figure 4. VTRNA2-1/PKR/CREB activated pathway leads to elevated IL-6 secretion in IgAN patients** (A)

191 ELISA assay showed significant increased levels of IL-6 in IgAN patients with VTRNA2-1/PKR/CREB activated

192 pathway respect to healthy group. (B) An IL-6 increase was found in T-IgAN patients with VTRNA2-1/PKR/CREB

193 activated pathway compared to TP group, even if not statistically significant. Both the levels of pPKR (C) and

194 pCREB (D) significantly correlated with IL-6 levels in IgAN patients (r=0.97, p= 0.0006 and r=0.89, p=0.0064,

195 respectively). Data are representative of 8 independent experiments (means ±SEM; * p-value < 0.05).

196

197

198

199 **Bacterial RNA viral RNA or COVID vaccine stimulation increase and imoxin decrease IL-6**
200 **secretion by PBMCs from HS and IgAN patients.**

201 The biological effect of triggering or blocking the PKR/CREB/IL-6 pathway on PBMCs from IgAN
202 patients and HS was studied. Since PKR can be activated by viral or bacterial RNA (25,26) (27,28)
203 lymphocytes were transfected with synthetic polyinosinic:polycytidylic acid (poly(I:C)), which
204 mimics viral dsRNA or with a COVID RNA vaccine. We found that the poly(I:C) and the vaccine
205 stimulation significantly increased the IL-6 secretion by PBMCs from both HS and IgAN patients
206 (Figure 5, $p<0.05$).

207 We then studied the effect of the PKR inhibitor imoxin on the IL-6 secretion. When IgAN patients
208 and HS PBMCs were stimulated with 1 μM imoxin, a drastic decrease in IL-6 levels was obtained
209 (Figure 6 A-B, $p<0.05$). Interestingly, Imoxin was effective also when used 48h after stimulation with
210 poly(I:C) (Figure 6C).



211

212 **Figure 5. poly(I:C) and COVID vaccine stimulation increase and imoxin decrease IL-6 secretion by PBMCs**
213 **from HS and IgAN patients.**
214 ELISA assay showing that the poly(I:C) (A) and the COVID vaccine (B) stimulation significantly increased the IL-
215 6 secretion by PBMCs from HS. (C) ELISA assay showing that imoxin (C16) significantly decrease the IL-6
216 secretion by PBMCs from HS. (D) ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion
217 by PBMCs from IgAN patients.
218



219
220 **Figure 6. PKR Inhibitor Imoxin decrease the IL-6 secretion even following viral RNA triggering**
221 ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion in PBMCS from HS, even when
222 used 48h after stimulation with poly(I:C).
223

224 **DISCUSSION**

225 The exact immunopathogenic mechanisms underlying IgAN are poorly understood. The original
226 multi-hit pathogenesis model integrates findings from studies on galactose-deficient IgA1, anti-
227 glycan response, formation, deposition of IgA1-containing immune complexes, and mechanisms of
228 immune complex-mediated tissue injury. Very recently the role of Il-6 in IgAN pathogenesis is
229 becoming increasingly important(29–33), even if the reason why levels of IL-6 are elevated in IgAN
230 patients is not well understood.

231 It selectively increases production of galactose-deficient IgA1 in IgA1-secreting cells from patients
232 with IgA nephropathy(29,30) and IL6-/- mice displayed no glomerular IgA deposition and were
233 protected from exacerbated renal failure following lipopolysaccharide treatment(32). Interestingly,
234 IL-6 signalling seems to be involved in this complex intestinal immune network particularly in
235 mediating the production of Gd-IgA(10,34).

236 One attainable hypothesis on high levels of IL-6 in IgAN comes out from our recent whole genome
237 DNA methylation screening in IgAN patients, that identified, among others, three regions with altered
238 DNA methylation capable of influencing the expression of genes involved in the response and
239 proliferation of T and B cells (15). We identified a hypermethylated region comprising Vault RNA
240 2-1 (VTRNA2-1), a non-coding RNA also known as precursor of miR-886 (pre-mi-RNA).
241 Consistently, the VTRNA2-1 expression was found down-regulated in IgAN patients(15).

242 Here we confirm that VTRNA2-1 is lower expressed in IgAN subjects compared to HS and we found
243 that also in transplanted IgAN patients compared to non IgAN transplanted patients the VTRNA2-1
244 transcript was expressed at level very low. The VTRNA2-1 gene produces an RNA polymerase III
245 transcript that resembles both a component of the ribonucleoprotein vault particle and a pre-
246 microRNA. However, the RNA product does not function as a vault or microRNA; rather, it acts as
247 a direct inhibitor of protein kinase R (also known as eukaryotic translation initiation factor 2-alpha
248 kinase 2, EIF2AK2), and thereby plays an important role in the regulation of cell growth. This gene
249 is nearby a differentially methylated region (DMR), is imprinted and may show allele-specific

250 expression. VTRNA2-1 is a metastable epiallele with accumulating evidence that methylation at this
251 region is heritable, modifiable, and associated with disease including risk and progression of
252 cancer(35).
253 We found that, in IgAN patients with downregulated VTRNA2-1, PKR is overactivated, coherently
254 with the role of the VTRNA2-1 that binds to PKR and inhibits its phosphorylation (36). The loss of
255 this natural restrain causes the activation of CREB, a classical cAMP-inducible CRE-binding factor
256 interacting with a region of the IL-6 promoter (that is known as CRE-like sequence), leading to IL-6
257 production (20–24).
258
259 The discovery of the upregulation of the PKR/CREB/IL-6 in IgAN patients is very suggestive. PKR
260 is normally activated by double-strand bacterial(25,26) and single-strand viral (27,28) RNA and has
261 long been recognized as a key mediator of the innate immunity response to viral infection. Expression
262 of latent PKR is induced by interferon and it is activated upon binding to viral RNA containing duplex
263 regions to undergo autophosphorylation. The data showing that, in IgAN patients, the PKR signalling
264 is already activated due to their epigenetic background could explain why the disease has traditionally
265 been considered as correlated to mucosal infections because of the clinical manifestation of hematuria
266 following upper respiratory tract microbes challenge(37,38). Bacterial and viral RNA may effectively
267 further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 production.
268 Moreover, recently has been found that, upon stimulation in vitro, the Epstein-Barr virus (EBV)-
269 infected IgA+ B cells secreted Gd-IgA1 and that B cells and their IgA+ subpopulation in PBMCs of
270 IgAN patients displayed a significantly higher frequency of EBV infection than did cells of the same
271 phenotype from non-IgAN patients(39). Interestingly, a different study very recently showed that
272 PKR is regulated by EBV RNA(40).
273 This kind of mechanism, driven by the epigenetic silencing of VTRNA2-1, may therefore explain
274 both the high levels of IL-6, and infection involvement in the disease, and recent data showing
275 microbiota involvment in IgAN (9) (41) (42). Our hypothesis is also supported by studies showing

276 that synthetic double-stranded RNA poly(I:C) stimulation promotes IgA class-switch recombination
277 and BAFF productions in tonsil mononuclear cells via the TLR3 pathway(43). Effectively, we
278 showed that both the RNA poly(I:C) and the COVID-19 RNA-vaccine stimulation significantly
279 increase the IL-6 levels in IgAN patient PBMCs.
280 Also, recent data showing 13 IgAN cases associated with COVID-19 infection and 4 cases of IgAN
281 following COVID-19 RNA-vaccination(44) may be clearly explained by our discovered mechanism
282 trough the PKR activation by RNA.
283
284 The PKR/CREB/IL-6 pathway may be very important also in the setting of renal transplantation. We
285 found that this pathway is upregulated also in IgAN transplanted patients. Recent studies showed that
286 the cumulative risk of IgA nephropathy recurrence increases after transplant and is associated with a
287 3.7-fold greater risk of graft loss(45). Besides, evidence suggests that IL-6 may play an important
288 role in donor-specific antibodies generation and chronic active antibody-mediated rejection and that
289 the treatment with an anti-IL-6 receptor monoclonal antibody may represent a novel approach for
290 chronic antibody-mediated rejection and transplant glomerulopathy, stabilizing allograft function and
291 extend patient lives (17).
292
293 Finally, we showed that the IL-6 secretion can be reduced by the PKR inhibitor imoxin. This drug
294 also known as C16 or imidazole, has shown beneficial effects on cell cultures and in vivo in animal
295 models for numerous conditions, such as improvement in inflammation, oxidative stress, diabetes,
296 suppression of tumor proliferation and in the control of hypertension. However, in light of our results,
297 it may be considered as a possible therapeutic drug also in IgAN (46). Interestingly, in mice dietary
298 exposure to the common foodborne mycotoxin deoxynivalenol (DON) upregulates serum
299 immunoglobulin A (IgA) and IL-6 miming IgAN and activating PKR/CREB/IL-6 pathway. The
300 dietary omega-3 fatty acids can invert these processes and ameliorate DON-induced IgA nephropathy
301 (12,13).

302

303 In conclusion, the discovery of the upregulated VTRNA2-1/PKR/CREB/IL-6 pathway in IgAN
304 patients may provide novel approach to treat the disease and may be useful for development of
305 precision nephrology and personalized therapy, possibly by checking the VTRNA2-1 methylation
306 level in IgAN patients.

307

308

309

310

311

312

313

314

315

316

317

318

319 **MATERIALS AND METHODS**

320

321 **Study design and patients**

322 The study was carried out in accordance with the Helsinki Declaration and the European Guidelines
323 for Good Clinical Practice and approved by our institutional ethics review. A total of 15 biopsy-
324 proven IgAN patients, 22 IgAN subjects with kidney transplant (T-IgAN), 14 patients transplanted
325 for causes other than IgAN (TP), and 10 Healthy subjects (HS) from south Italy were included in the
326 study after providing their written informed consent.

327 PBMCs were isolated by gradient centrifugation with Ficoll-Hypaque (Euroclone, Italy) from
328 heparinized venous blood from patients and HS. PBMCs were cultured in RPMI 1640 (Euroclone)
329 supplemented with 10% Fetal Bovine Serum (Euroclone), 100U/mL Penicillin/Streptomycin
330 (Euroclone), 4mMGlutamine (Euroclone), 10 mM Hepes (Sigma), 0.1 mM non-essential amino acids
331 (Euroclone), 1mM sodium pyruvate and 50 U/mL, rhIL-2.

332

333 **RNA extraction and real time-PCR expression of VTRNA2-1, CREB and PKR**

334 Total RNA were isolated from PBMCs of IgAN, T-IgAN, TP and HS using RNeasy Mini Kit (Qiagen,
335 Hilden, Germany) according to the manufacturer's instruction and quantified by NanoDrop One
336 Spectrophotometer (thermoFisher Scientific). Total RNA was retro-transcribed using the miScript II
337 RT Kit with iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA)following the manufacturer's
338 instructions.

339 Real Time-PCR was performed on a StepOne Plus instrument (Applied Biosystems) by using
340 VTRNA2-1, PKR and CREB primers (Integrated DNA Technologies, Coralville,
341 IA,USA) GAPDH gene amplification was used as a reference standard to normalize the target signal.
342 Real Time-PCR was performed in triplicate, and relative expression was calculated using the $2^{-\Delta C_t}$
343 method.

344

345 **pPKR/pCREB/IL-6 pathway ELISA quantification**

346 Colorimetric Cell-Based ELISA assays were used to detect the levels of CREB/pCREB (CREB
347 (Phospho-Ser142) Aviva Systems Biology, USA), and PKR/pPKR (PKR (Phospho-Thr258) Aviva
348 Systems Biology, USA).

349 Briefly, PBMCs of HS, IgAN, T-IgAN and TP subjects were freshly isolated and seeded overnight
350 with RPMI medium at 37°C, 5% CO_2, in a 96-Well Cell Culture Clear-Bottom Microplate. The
351 ELISA assay protocols were executed following manufacturer instructions.

352 To determine IL-6 levels, PBMCs of HS, IgAN, T-IgAN and TP subjects, were freshly isolated and
353 seeded in a 96-Well Cell Culture Microplate supplemented with RPMI medium at 37°C, 5% CO_2.
354 After 48 h of culture, cells were collected and, centrifuged at 230 rpm for 15 minutes. Supernatant
355 were recovered and analysed using Human IL-6 Quantikine ELISA Kit (R&D Systems, USA),
356 following manufacturer's protocol.

357 Optical densities were determined using a microplate reader (programmable MPT reader model DV
358 990BV6; GDV, Italy) set to 450 nm.

359

360 **Transfection experiments**

361 PBMCs of HS and IgAN patients were seeded in 6-well plates at a density of 2 x 10^6 cells/cm^2 and
362 were incubated with specific medium. Xfect Transfection Reagent (Clontech,Takara bio, France) was
363 used to transfect 20 ug of Poly (I:C) (InvivoGen, Europe), a synthetic analogue of dsRNA, in PBMC
364 cells, according to manufacturer's instructions. Imoxin (Chem Cruz) was added to PBMCs at a
365 concentration of 1 μM. After two days of incubation with Poly (I:C) and/or Imoxin the secretion of
366 IL-6 levels by PBMCs were measured in the cell culture supernatants.

367

368 **Statistical Analysis**

369 Statistical analyses were performed using the Student's t-test, as appropriate. A p-value < 0.05 was
370 considered significant. Data are expressed as means ± SEM.

371 **REFERENCES**

372

373 1. Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. *Clinical Journal of the American Society*
374 *of Nephrology* (2017) **12**:677–686. doi: 10.2215/CJN.07420716

375 2. Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. *Clinical and*
376 *Experimental Nephrology 2018 23:1* (2018) **23**:26–31. doi: 10.1007/S10157-018-1582-2

377 3. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F,
378 Mestecky J, Gharavi AG, et al. The Pathophysiology of IgA Nephropathy. doi:
379 10.1681/ASN.2011050464

380 4. Sallustio F, Cox SN, Serino G, Curci C, Pesce F, De Palma G, Papagianni A, Kirmizis D,
381 Falchi M, Schena FP. Genome-wide scan identifies a copy number variable region at 3p21.1
382 that influences the TLR9 expression levels in IgA nephropathy patients. *European Journal of*
383 *Human Genetics 2015 23:7* (2014) **23**:940–948. doi: 10.1038/ejhg.2014.208

384 5. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK, Mizoguchi E, Geha RS. Impaired
385 IgA class switching in APRIL-deficient mice. *Proceedings of the National Academy of*
386 *Sciences* (2004) **101**:3903–3908. doi: 10.1073/PNAS.0307348101

387 6. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash
388 S, Shapiro S, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved
389 in immunity against intestinal pathogens. *Nature Genetics 2014 46:11* (2014) **46**:1187–1196.
390 doi: 10.1038/ng.3118

391 7. Coppo R. The intestine–renal connection in IgA nephropathy. *Nephrology Dialysis*
392 *Transplantation* (2015) **30**:360–366. doi: 10.1093/NDT/GFU343

393 8. Papista C, Lechner S, Mkaddem S Ben, LeStang M-B, Abbad L, Bex-Coudrat J, Pillebout E,
394 Chemouny JM, Jablonski M, Flamant M, et al. Gluten exacerbates IgA nephropathy in
395 humanized mice through gliadin–CD89 interaction. *Kidney International* (2015) **88**:276–285.
396 doi: 10.1038/KI.2015.94

397 9. Sallustio F, Curci C, Chaoul N, Fontò G, Lauriero G, Picerno A, Divella C, di Leo V, de
398 Angelis M, ben Mkaddem S, et al. High levels of gut-homing immunoglobulin A-positive+B
399 lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in
400 immunoglobulin A nephropathy patients. *Nephrology, dialysis, transplantation : official*
401 *publication of the European Dialysis and Transplant Association - European Renal*
402 *Association* (2020) doi: 10.1093/ndt/gfaa264
403 10. Rops ALWMM, Jansen E, van der Schaaf A, Pieterse E, Rother N, Hofstra J, Dijkman HBPM,
404 van de Logt AE, Wetzels J, van der Vlag J, et al. Interleukin-6 is essential for glomerular
405 immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.
406 *Kidney International* (2018) **93**:1356–1366. doi: 10.1016/J.KINT.2018.01.005
407 11. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
408 induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA
409 nephropathy. *Kidney International* (2020) **97**:340–349. doi: 10.1016/J.KINT.2019.08.022
410 12. Pestka JJ. Deoxynivalenol-induced IgA production and IgA nephropathy-aberrant mucosal
411 immune response with systemic repercussions. *Toxicology Letters* (2003) **140–141**:287–295.
412 doi: 10.1016/S0378-4274(03)00024-9
413 13. Shi Y, Pestka JJ. Mechanisms for suppression of interleukin-6 expression in peritoneal
414 macrophages from docosahexaenoic acid-fed mice. *Journal of Nutritional Biochemistry* (2009)
415 **20**:358–368. doi: 10.1016/J.JNUTBIO.2008.04.006
416 14. Yan D, Zhou HR, Brooks KH, Pestka JJ. Potential role of IL-5 and IL-6 in enhanced IgA
417 secretion by Peyer's patch cells isolated from mice acutely exposed to vomitoxin. *Toxicology*
418 (1997) **122**:145–158. doi: 10.1016/S0300-483X(97)00087-5
419 15. Sallustio F, Serino G, Cox SN, Gassa AD, Curci C, De Palma G, Banelli B, Zaza G, Romani
420 M, Schena FP. Aberrantly methylated DNA regions lead to low activation of CD4+ T-cells in
421 IgA nephropathy. *Clinical Science* (2016) **130**:733–746. doi: 10.1042/CS20150711

422 16. Kim I, Wu G, Chai N, Klein AS, Jordan S. Anti-interleukin 6 receptor antibodies attenuate
423 antibody recall responses in a mouse model of allosensitization. *Transplantation* (2014)
424 **98**:1262–70. doi: 10.1097/TP.0000000000000437
425 17. Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, et
426 al. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential
427 Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-
428 Sensitized Renal Allograft Recipients. *American journal of transplantation : official journal*
429 *of the American Society of Transplantation and the American Society of Transplant Surgeons*
430 (2017) **17**:2381–2389. doi: 10.1111/ajt.14228
431 18. Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, Bang JY, Park HS, Leelayuwat
432 C, Lee YS. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with
433 PKR and modulates its activity. *RNA* (2011) **17**:1076–1089. doi: 10.1261/rna.2701111
434 19. Shi Y, Pestka JJ. Mechanisms for suppression of interleukin-6 expression in peritoneal
435 macrophages from docosahexaenoic acid-fed mice. *The Journal of nutritional biochemistry*
436 (2009) **20**:358–68. doi: 10.1016/j.jnutbio.2008.04.006
437 20. Spooren A, Kooijman R, Lintermans B, van Craenenbroeck K, Vermeulen L, Haegeman G,
438 Gerlo S. Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in
439 astrocytes. *Cellular signalling* (2010) **22**:871–81. doi: 10.1016/j.cellsig.2010.01.018
440 21. Ishizu A, Abe A, Miyatake Y, Baba T, Iinuma C, Tomaru U, Yoshiki T. Cyclic AMP response
441 element-binding protein is implicated in IL-6 production from arthritic synovial cells. *Modern*
442 *rheumatology* (2010) **20**:134–8. doi: 10.1007/s10165-009-0245-2
443 22. Yang R, Lin Q, Gao HB, Zhang P. Stress-related hormone norepinephrine induces interleukin-
444 6 expression in GES-1 cells. *Brazilian journal of medical and biological research = Revista*
445 *brasileira de pesquisas medicas e biologicas* (2014) **47**:101–9. doi: 10.1590/1414-
446 431X20133346

447 23. Luo Y, Zheng SG. Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and
448 Its Transcriptional Regulation Mechanisms. *Frontiers in Immunology* (2016) **7**:604. doi:
449 10.3389/fimmu.2016.00604
450 24. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6 gene
451 mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. *Molecular and*
452 *cellular biology* (1994) **14**:4443–54. doi: 10.1128/mcb.14.7.4443-4454.1994
453 25. Bleiblo F, Michael P, Brabant D, Ramana C v., Tai T, Saleh M, Parrillo JE, Kumar A, Kumar
454 A. Bacterial RNA induces myocyte cellular dysfunction through the activation of PKR.
455 *Journal of Thoracic Disease* (2012) **4**: doi: 10.3978/J.ISSN.2072-1439.2012.01.07
456 26. Hull CM, Bevilacqua PC. Mechanistic Analysis of Activation of the Innate Immune Sensor
457 PKR by Bacterial RNA. *Journal of molecular biology* (2015) **427**:3501–3515. doi:
458 10.1016/j.jmb.2015.05.018
459 27. García MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: virus and cell control.
460 *Biochimie* (2007) **89**:799–811. doi: 10.1016/j.biochi.2007.03.001
461 28. Pindel A, Sadler A. The role of protein kinase R in the interferon response. *Journal of*
462 *interferon & cytokine research : the official journal of the International Society for Interferon*
463 *and Cytokine Research* (2011) **31**:59–70. doi: 10.1089/jir.2010.0099
464 29. Zhang J, Mi Y, Zhou R, Liu Z, Huang B, Guo R, Wang P, Lu Y, Zhou Y, Quan S. The TLR4-
465 MyD88-NF-κB pathway is involved in sIgA-mediated IgA nephropathy. *Journal of*
466 *nephrology* (2020) **33**:1251–1261. doi: 10.1007/s40620-020-00722-3
467 30. Yamada K, Huang Z-Q, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z,
468 Kiryluk K, Suzuki Y, et al. Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen
469 Production in IgA Nephropathy. *Kidney International Reports* (2017) **2**:1194–1207. doi:
470 10.1016/j.ekir.2017.07.002

471 31. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
472 induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA
473 nephropathy. *Kidney International* (2020) doi: 10.1016/j.kint.2019.08.022
474 32. Rops ALWMM, Jansen E, van der Schaaf A, Pieterse E, Rother N, Hofstra J, Dijkman HBPM,
475 van de Logt AE, Wetzels J, van der Vlag J, et al. Interleukin-6 is essential for glomerular
476 immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.
477 *Kidney International* (2018) **93**:1356–1366. doi: 10.1016/j.kint.2018.01.005
478 33. Si R, Zhao P, Yu Z, Qu Z, Sun W, Li T, Jiang Y. Increased Non-switched Memory B Cells are
479 Associated with Plasmablasts, Serum IL-6 Levels and Renal Functional Impairments in IgAN
480 Patients. *Immunological Investigations* (2020) doi: 10.1080/08820139.2019.1683026
481 34. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
482 induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA
483 nephropathy. *Kidney International* (2020) **97**:340–349. doi: 10.1016/J.KINT.2019.08.022
484 35. Dugué P-A, Yu C, McKay T, Wong EM, Joo JE, Tsimiklis H, Hammet F, Mahmoodi M, Theys
485 D, kConFab, et al. VTRNA2-1: Genetic Variation, Heritable Methylation and Disease
486 Association. *International Journal of Molecular Sciences* (2021) **22**:2535. doi:
487 10.3390/ijms22052535
488 36. Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang G-Y, Bang JY, Park HS, Leelayuwat
489 C, Lee YS. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with
490 PKR and modulates its activity. *RNA* (2011) **17**:1076–1089. doi: 10.1261/RNA.2701111
491 37. He J-W, Zhou X-J, Lv J-C, Zhang H. Perspectives on how mucosal immune responses,
492 infections and gut microbiome shape IgA nephropathy and future therapies. *Theranostics*
493 (2020) **10**:11462–11478. doi: 10.7150/thno.49778
494 38. Rollino C, Vischini G, Coppo R. IgA nephropathy and infections. *Journal of Nephrology*
495 (2016) **29**:463–468. doi: 10.1007/s40620-016-0265-x

496 39. Zachova K, Kosztyu P, Zadrazil J, Matousovic K, Vondrak K, Hubacek P, Julian BA,
497 Moldoveanu Z, Novak Z, Kostovcikova K, et al. Role of Epstein-Barr Virus in Pathogenesis
498 and Racial Distribution of IgA Nephropathy. *Frontiers in Immunology* (2020) **11**:267. doi:
499 10.3389/fimmu.2020.00267
500 40. Zerbe CM, Cole JL. Regulation of Protein Kinase R by Epstein-Barr Virus EBER1 RNA.
501 *Biochemistry* (2020) **59**:1252–1260. doi: 10.1021/acs.biochem.0c00088
502 41. He JW, Zhou XJ, Lv JC, Zhang H. Perspectives on how mucosal immune responses, infections
503 and gut microbiome shape iga nephropathy and future therapies. *Theranostics* (2020)
504 **10**:11462–11478. doi: 10.7150/THNO.49778
505 42. Angelis M De, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G,
506 Serrazanetti D, Dalfino G, Gobbetti M, et al. Microbiota and Metabolome Associated with
507 Immunoglobulin A Nephropathy (IgAN). *PLOS ONE* (2014) **9**:e99006. doi:
508 10.1371/JOURNAL.PONE.0099006
509 43. He L, Peng X, Wang J, Tang C, Zhou X, Liu H, Liu F, Sun L, Peng Y. Synthetic double-
510 stranded RNA Poly(I:C) aggravates IgA nephropathy by triggering IgA class switching
511 recombination through the TLR3-BAFF axis. *American Journal of Nephrology* (2015)
512 **42**:185–197. doi: 10.1159/000440819
513 44. Farooq H, Aemaz Ur Rehman M, Asmar A, Asif S, Mushtaq A, Qureshi MA. The pathogenesis
514 of COVID-19-induced IgA nephropathy and IgA vasculitis: A systematic review. *Journal of*
515 *Taibah University Medical Sciences* (2021) doi: 10.1016/j.jtumed.2021.08.012
516 45. Uffing A, Pérez-Saéz MJ, Jouve T, Bugnazet M, Malvezzi P, Muhsin SA, Lafargue M-C,
517 Reindl-Schwaighofer R, Morlock A, Oberbauer R, et al. Recurrence of IgA Nephropathy after
518 Kidney Transplantation in Adults. *Clinical journal of the American Society of Nephrology :*
519 *CJASN* (2021) **16**:1247–1255. doi: 10.2215/CJN.00910121

46. Kalra J, Dasari D, Bhat A, Mangali S, Goyal SG, Jadhav KB, Dhar A. PKR inhibitor imoxin prevents hypertension, endothelial dysfunction and cardiac and vascular remodelling in L-NAME-treated rats. *Life Sciences* (2020) **262**: doi: 10.1016/J.LFS.2020.118436

531 **FIGURE LEGENDS**

532

533 **Figure 1. VTRNA2-1 expression in real-time PCR.** (A)Real-time PCR of VTRNA2-1 transcript
534 differentially expressed in PBMCs of IgAN and HS. (B) Real-time PCR of VTRNA2-1 transcript
535 differentially expressed in PBMCs of T-IgAN and TP. Data are expressed as mean ± SEM, (* p-value
536 < 0.05, ****p-value <0.001).

537

538 **Figure 2. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated PKR**
539 (A) ELISA assay showed significantly increased level of phosphorylated PKR in IgAN patients
540 respect to healthy group (HS). (B) A strong increase in phospho-PKR levels was found in T-IgAN
541 patients compared to TP group. (C) Gene expression of PKR in IgAN patients and HS. (D) Gene
542 expression of PKR in TP and T-IgAN patients. Data are representative of 8 independent experiments
543 (means ±SEM; * p-value < 0.05).

544
545

546 **Figure 3. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated CREB**
547 (A) The assay revealed systemic activation of CREB (phospho-Thr305-CREB) in IgAN group
548 compared to healthy subjects (HS). (B) CREB phosphorylation was also significantly increased in T-
549 IgAN patients compared to transplanted patients without IgAN disease. (C) Gene expression of
550 CREB in IgAN patients and HS. (D) Gene expression of CREB in TP and T-IgAN patients. Data are
551 representative of 8 independent experiments (means ±SEM; * p-value < 0.05, ****p-value <0.001).

552

553 **Figure 4. VTRNA2-1/PKR/CREB activated pathway leads to elevated IL-6 secretion in IgAN**
554 **patients** (A) ELISA assay showed significant increased levels of IL-6 in IgAN patients with
555 VTRNA2-1/PKR/CREB activated pathway respect to healthy group. (B) An IL-6 increase was found
556 in T-IgAN patients with VTRNA2-1/PKR/CREB activated pathway compared to TP group, even if

557 not statistically significant. Both the levels of pPKR (C) and pCREB (D) significantly correlated with
558 IL-6 levels in IgAN patients (r=0.97, p= 0.0006 and r=0.89, p=0.0064, respectively). Data are
559 representative of 8 independent experiments (means ±SEM; * p-value < 0.05).
560
561 **Figure 5. poly(I:C) and COVID vaccine stimulation increase and imoxin decrease IL-6**
562 **secretion by PBMCs from HS and IgAN patients.**
563 ELISA assay showing that the poly(I:C) (A) and the COVID vaccine (B) stimulation significantly
564 increased the IL-6 secretion by PBMCs from HS. (C) ELISA assay showing that imoxin (C16)
565 significantly decrease the IL-6 secretion by PBMCs from HS. (D) ELISA assay showing that imoxin
566 (C16) significantly decrease the IL-6 secretion by PBMCs from IgAN patients.
567
568 **Figure 6. PKR Inhibitor Imoxin decrease the IL-6 secretion even following viral RNA triggering**
569 ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion in PBMCS from
570 HS, even when used 48h after stimulation with poly(I:C).
571
572